サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1791563

細胞・遺伝子治療臨床試験サービスの世界市場

Cell and Gene Therapy Clinical Trial Services

出版日
ページ情報
英文 154 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.73円
細胞・遺伝子治療臨床試験サービスの世界市場
出版日: 2025年08月15日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 154 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞・遺伝子治療臨床試験サービスの世界市場は2030年までに289億米ドルに達する見込み

2024年に117億米ドルと推定される細胞・遺伝子治療臨床試験サービスの世界市場は、2024年から2030年にかけてCAGR 16.3％で成長し、2030年には289億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズiは、CAGR17.9%を記録し、分析期間終了時には151億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間中CAGR 15.8％と推定されます。

米国市場は31億米ドルと推定、中国はCAGR15.3％で成長予測

米国の細胞・遺伝子治療臨床試験サービス市場は、2024年に31億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに44億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは15.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ15.2％と13.9％と予測されています。欧州では、ドイツがCAGR 11.8%で成長すると予測されています。

世界の細胞・遺伝子治療臨床試験サービス市場- 主要動向と促進要因まとめ

なぜ細胞・遺伝子治療臨床試験サービスの需要が増加しているのか？

細胞・遺伝子治療臨床試験サービスの需要が増加している背景には、開発パイプラインに入る革新的な治療法の数の増加、個別化医療の台頭、先端治療製品に対する規制当局の支援の拡大などがあります。細胞療法や遺伝子療法は、希少な遺伝性疾患、がん、神経変性疾患など、これまで治療不可能であった疾患の治療に大きな可能性を示しています。製薬会社やバイオテクノロジー企業が再生医療への投資を続ける中、専門的な臨床試験サービスに対するニーズは飛躍的に高まっています。

遺伝子工学、CRISPRに基づく技術、自家および同種細胞療法の開発は、この分野の研究開発をさらに加速させています。希少疾患や腫瘍を対象とした臨床試験の増加に伴い、医薬品開発業務受託機関や専門的な臨床試験サービスプロバイダーは、規制遵守、患者募集、試験実施の確保において重要な役割を果たしています。さらに、FDAやEMAなどの世界の規制機関は、細胞・遺伝子治療に対する合理化された承認経路を導入しており、複雑な規制状況を乗り切るための臨床試験の専門知識に対する需要が高まっています。

技術の進歩は細胞・遺伝子治療の臨床試験をどのように改善しているか？

臨床試験デザイン、リアルタイムモニタリング、患者データ分析における技術革新は、細胞・遺伝子治療試験の実施に革命をもたらしています。最も重要な進歩のひとつは、人工知能と機械学習を用いて、患者募集と治療結果の予測モデリングを最適化することです。AI主導の試験デザインは、適切な候補者の特定、試験効率の向上、画期的な治療法の市場投入までの時間短縮に役立っています。

もう一つの大きなブレークスルーは、遠隔患者モニタリングを可能にし、従来の試験デザインに伴うロジスティクスの課題を軽減する分散型臨床試験の統合です。ウェアラブルバイオセンサー、遠隔医療プラットフォーム、電子患者報告アウトカムにより、治験はより患者中心に行われるようになり、コンプライアンスとデータ収集がより確実になります。さらに、細胞ベースの治療法における凍結保存とロジスティクスの進歩により、多施設・国際共同試験の実施能力が向上しています。ラボプロセスの自動化とゲノム解析のためのバイオインフォマティクスツールの増加により、細胞・遺伝子治療試験はより正確でスケーラブルかつ効率的になりつつあります。

細胞・遺伝子治療臨床試験サービス業界の成長を牽引する市場動向は？

希少疾患や腫瘍を対象とした臨床試験の増加は、細胞・遺伝子治療臨床試験サービス市場を形成する最も影響力のある動向の一つです。これらの治療法の多くは少数の患者集団を対象としており、複雑な治療プロトコールに合わせた特殊なリクルート戦略や試験デザインが必要となります。また、再生医療や免疫療法に基づく治療の拡大により、細胞を用いた治療特有の課題に対応するカスタマイズされた試験サービスへのニーズも高まっています。

市場成長に影響を与えるもう一つの主要動向は、製薬企業、研究機関、開発業務受託機関の世界の協力関係の高まりです。細胞治療や遺伝子治療の臨床試験には専門施設、熟練した人材、高度な製造能力が必要とされるため、企業は経験豊富なサービスプロバイダーに臨床試験管理を委託する傾向が強まっています。さらに、異なる地域間での規制の調和がより迅速な承認を促し、企業が多施設共同試験をより効率的に実施することを可能にしています。また、治療評価におけるリアルワールドエビデンスの役割の増大は、長期的な患者の転帰を承認や償還戦略に組み込むことで、臨床試験手法を形成しつつあります。

細胞・遺伝子治療臨床試験サービス市場の将来を形成する主な成長促進要因とは？

細胞・遺伝子治療臨床試験サービス市場の成長は、再生医療への投資の増加、高度なバイオ製造技術の台頭、新規治療をサポートする規制の枠組みの進化など、いくつかの要因によってもたらされます。主な成長要因のひとつは、官民双方から細胞・遺伝子治療研究に多額の資金が投入されていることであり、政府やベンチャーキャピタルは次世代治療に多額の投資を行っています。

市場を形成するもう一つの重要な促進要因は、先端療法に特化した専門研究センターや製造拠点など、臨床試験インフラの拡大です。個別化治療の需要が高まる中、治験サービスプロバイダーは、治療の有効性と患者の転帰を改善するため、適応性のある試験デザインと精密医療アプローチに注力しています。さらに、分散型やハイブリッド型の臨床試験モデルが受け入れられつつあることで、より広範な患者の参加が可能になり、臨床試験コストが削減されています。細胞・遺伝子治療の分野が進化を続ける中、臨床試験サービスは、革新的な治療法を市場に投入し、複雑な疾患に対処し、精密医療の未来を前進させる上で、引き続き不可欠です。

セグメント

フェーズ（フェーズI、フェーズII、フェーズIII、フェーズIV）、適応症（腫瘍学適応症、中枢神経系適応症、心臓病適応症、眼科適応症、免疫・炎症適応症、血液学適応症、筋骨格系適応症、内分泌・代謝・遺伝子適応症、感染症適応症、その他の適応症）

調査対象企業の例

  • Charles River Laboratories
  • Clinipace
  • Covance Inc.
  • ICON plc
  • IQVIA Biotech
  • KCR
  • Labcorp Drug Development
  • Linical Co., Ltd.
  • Medpace
  • Novotech
  • Parexel International
  • Pivotal Clinical Research
  • PPD（Thermo Fisher Scientific）
  • PRA Health Sciences
  • Premier Research
  • Syneos Health
  • Synteract
  • Veristat
  • Worldwide Clinical Trials
  • WuXi AppTec

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP29863

Global Cell and Gene Therapy Clinical Trial Services Market to Reach US$28.9 Billion by 2030

The global market for Cell and Gene Therapy Clinical Trial Services estimated at US$11.7 Billion in the year 2024, is expected to reach US$28.9 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$15.1 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 15.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.1 Billion While China is Forecast to Grow at 15.3% CAGR

The Cell and Gene Therapy Clinical Trial Services market in the U.S. is estimated at US$3.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.4 Billion by the year 2030 trailing a CAGR of 15.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.2% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.8% CAGR.

Global Cell and Gene Therapy Clinical Trial Services Market - Key Trends & Drivers Summarized

Why Is the Demand for Cell and Gene Therapy Clinical Trial Services Increasing?

The demand for cell and gene therapy clinical trial services is increasing due to the growing number of innovative therapies entering the development pipeline, the rise of personalized medicine, and the expanding regulatory support for advanced therapeutic products. Cell and gene therapies have shown significant potential in treating previously untreatable conditions, including rare genetic disorders, cancers, and neurodegenerative diseases. As pharmaceutical and biotech companies continue investing in regenerative medicine, the need for specialized clinical trial services has grown exponentially.

Advancements in genetic engineering, CRISPR-based technologies, and autologous and allogeneic cell therapies have further accelerated research and development efforts in this field. With a rise in clinical trials targeting rare diseases and oncology, contract research organizations and specialized trial service providers are playing a critical role in ensuring regulatory compliance, patient recruitment, and trial execution. Additionally, global regulatory agencies such as the FDA and EMA are introducing streamlined approval pathways for cell and gene therapies, increasing the demand for clinical trial expertise to navigate the complex regulatory landscape.

How Are Technological Advancements Improving Cell and Gene Therapy Clinical Trials?

Technological innovations in clinical trial design, real-time monitoring, and patient data analytics are revolutionizing the execution of cell and gene therapy studies. One of the most significant advancements is the use of artificial intelligence and machine learning to optimize patient recruitment and predictive modeling for therapy outcomes. AI-driven trial design helps identify suitable candidates, improve trial efficiency, and reduce time-to-market for breakthrough therapies.

Another major breakthrough is the integration of decentralized clinical trials, which enable remote patient monitoring and reduce the logistical challenges associated with traditional study designs. Wearable biosensors, telemedicine platforms, and electronic patient-reported outcomes are making trials more patient-centric, ensuring better compliance and data collection. Additionally, advancements in cryopreservation and logistics for cell-based therapies are enhancing the ability to conduct multi-site and global trials. With increasing automation in laboratory processes and bioinformatics tools for genomic analysis, cell and gene therapy trials are becoming more precise, scalable, and efficient.

Which Market Trends Are Driving Growth in the Cell and Gene Therapy Clinical Trial Services Industry?

The increasing number of clinical trials focused on rare diseases and oncology is one of the most influential trends shaping the cell and gene therapy clinical trial services market. Many of these therapies target small patient populations, requiring specialized recruitment strategies and trial designs tailored to complex treatment protocols. The expansion of regenerative medicine and immunotherapy-based treatments has also led to a growing need for customized trial services that address the unique challenges of cell-based interventions.

Another key trend influencing market growth is the rise of global collaborations between pharmaceutical companies, research institutions, and contract research organizations. As cell and gene therapy trials require specialized facilities, skilled personnel, and advanced manufacturing capabilities, companies are increasingly outsourcing clinical trial management to experienced service providers. Additionally, regulatory harmonization across different regions is facilitating faster approvals, allowing companies to conduct multi-center trials more efficiently. The increasing role of real-world evidence in therapy assessment is also shaping clinical trial methodologies, integrating long-term patient outcomes into approval and reimbursement strategies.

What Are the Key Growth Drivers Shaping the Future of the Cell and Gene Therapy Clinical Trial Services Market?

The growth in the cell and gene therapy clinical trial services market is driven by several factors, including increased investment in regenerative medicine, the rise of advanced biomanufacturing techniques, and evolving regulatory frameworks supporting novel therapies. One of the primary growth drivers is the significant funding from both public and private sectors into cell and gene therapy research, with governments and venture capital firms heavily investing in next-generation treatments.

Another crucial driver shaping the market is the expansion of clinical trial infrastructure, including specialized research centers and manufacturing hubs dedicated to advanced therapies. As the demand for personalized treatments increases, trial service providers are focusing on adaptive trial designs and precision medicine approaches to improve therapy efficacy and patient outcomes. Additionally, the increasing acceptance of decentralized and hybrid trial models is enabling wider patient participation and reducing trial costs. As the field of cell and gene therapy continues to evolve, clinical trial services will remain essential in bringing transformative treatments to market, addressing complex diseases, and advancing the future of precision medicine.

SCOPE OF STUDY:

The report analyzes the Cell and Gene Therapy Clinical Trial Services market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Indication (Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication, Immunology and Inflammation Indication, Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • Charles River Laboratories
  • Clinipace
  • Covance Inc.
  • ICON plc
  • IQVIA Biotech
  • KCR
  • Labcorp Drug Development
  • Linical Co., Ltd.
  • Medpace
  • Novotech
  • Parexel International
  • Pivotal Clinical Research
  • PPD (Thermo Fisher Scientific)
  • PRA Health Sciences
  • Premier Research
  • Syneos Health
  • Synteract
  • Veristat
  • Worldwide Clinical Trials
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cell and Gene Therapy Clinical Trial Services - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surging Pipeline of Advanced Therapies Throws the Spotlight on Specialized Cell and Gene Therapy (CGT) Clinical Trial Services
    • Increasing Complexity of CGT Trial Protocols Propels Demand for Niche CRO Expertise and Infrastructure
    • Growth in Orphan and Rare Disease Drug Development Expands the Addressable Market for CGT Clinical Trial Providers
    • Expansion of Personalized and Autologous Therapies Strengthens the Business Case for Highly Customized Trial Designs
    • High Manufacturing and Supply Chain Sensitivities Spur Need for Integrated CGT Logistics and Trial Coordination Services
    • Globalization of CGT Trials Fuels Demand for Multiregional Site Management and Regulatory Navigation Support
    • Emergence of Decentralized and Hybrid Trial Models Enhances Patient Accessibility and Enrollment for CGT Studies
    • Advanced Biomarker and Companion Diagnostic Development Drives Demand for Integrated Bioanalytical Services
    • Innovations in Digital Health Tools and eSource Data Collection Streamline Complex CGT Trial Operations
    • Specialized Patient Recruitment Strategies Become Critical in Ultra-Niche CGT Trial Populations
    • Increasing Role of Real-World Evidence and Long-Term Follow-Up Requirements Extends Scope of CGT Trial Services
    • Cell Banking, Cryopreservation, and Chain-of-Custody Protocols Drive Infrastructure Investment in Trial Support Services
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cell and Gene Therapy Clinical Trial Services Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Hematology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Hematology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Musculoskeletal Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Musculoskeletal Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Endocrine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Endocrine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Metabolic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Metabolic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Genetic Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Genetic Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Infectious Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Infectious Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for CNS Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for CNS Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Cardiology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Cardiology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Ophthalmology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Ophthalmology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Immunology & Inflammation Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Immunology & Inflammation Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 36: USA Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • JAPAN
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 46: Japan Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Japan 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • CHINA
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 48: China Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • EUROPE
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • FRANCE
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • GERMANY
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • UNITED KINGDOM
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: UK 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Rest of Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Cell and Gene Therapy Clinical Trial Services Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 78: Asia-Pacific Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Asia-Pacific 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Asia-Pacific 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 82: Rest of World Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of World 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2025 & 2030
    • TABLE 84: Rest of World Recent Past, Current & Future Analysis for Cell and Gene Therapy Clinical Trial Services by Indication - Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of World 6-Year Perspective for Cell and Gene Therapy Clinical Trial Services by Indication - Percentage Breakdown of Value Sales for Hematology Indication, Musculoskeletal Indication, Endocrine, Metabolic, Genetic Indication, Infectious Diseases Indication, Other Indications, Oncology Indication, CNS Indication, Cardiology Indication, Ophthalmology Indication and Immunology & Inflammation Indication for the Years 2025 & 2030

IV. COMPETITION